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Genetic Alterations Between Primary Head
and Neck Squamous Cell Carcinoma and
Recurrence After Radiotherapy
Recurrence, Genetically Related Cancer, or Second Primary?
Alberto Deganello, MD1; Alessandro Franchi, MD2; Iacopo Sardi, MD3; Lorenzo Pignataro, MD4;
C. Rene´ Leemans, MD, PhD5; and Oreste Gallo, MD1
BACKGROUND: In the attempt to characterize the genetic bases of recurrent head and neck squamous cell carci-
noma (HNSCC) after radiotherapy (RT), the authors compared the molecular profiles of primary tumors and recur-
rences. METHODS: TP53 gene status and instability at 10 microsatellite markers were determined in pre-RT lesions
and corresponding local recurrences in a series of 16 HNSCCs. RESULTS: Eight (50%) HNSCCs showed both TP53
and microsatellite instability (MSI) status concordance in pre- and postirradiation biopsies; 3 (18.7%) showed discord-
ance of both TP53 and MSI status; and finally 5 (31.2%) had discordance at only 1 genetic test. Accordingly, the
authors interpreted as true recurrence the 8 concordant cases, and as true second primary malignancies the 3 dis-
cordant ones. In the remaining 5 cases with partial DNA correspondence, the exact nature of the new lesion only par-
tially related to the original cancer is a matter of discussion. Patients showing the same mutations among pre- and
post-RT HNSCCs had a longer disease-free interval (DFI) and better survival than those showing discordant genetic
features (log-rank test, P ¼ .0045). CONCLUSIONS: Post-RT recurrent HNSCCs are genetically heterogeneous. The
genetic characterization of the recurrence, especially in those cases with a particularly short DFI showing partially
discordant mutations, might have a useful clinical relevance in the restaging process. Cancer 2010; :000–000.
VC 2010 American Cancer Society.
KEYWORDS: head and neck squamous cell carcinoma, radiotherapy, local recurrence, TP53, microsatellite instability,
second field tumor, minimal residual disease.
Radiotherapy (RT) plays a significant role in the treatment of head and neck squamous cell carcinoma (HNSCC).
Some tumors fail to respond to this approach because of the appearance of resistant populations. The persistence or recur-
rence of the disease after irradiation is usually a poor prognostic factor, because it is frequently associated with unrespon-
siveness to other therapies and high risk of regional and distant metastases.
Currently, no universally accepted definition of post-RT recurrence HNSCC exists. Furthermore, the time of tumor
relapse is also extremely variable, ranging from fewmonths to 5 years post-RT. This heterogeneity may reflect the possibil-
ity that the reappearance of a HNSCC in the same field as a previously RT-treated lesion could represent the development
of a second primarymalignancy in a field that had been exposed to chemical carcinogens, such as tobacco, alcohol, and pre-
vious RT.
Recent studies in the area of cancer genetics have better characterized the possibility that, according to Slaughter’s hy-
pothesis, unexpected local recurrences after surgery occurring very close to the site of primary lesions (within 2 cm) and
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with a well-defined time interval from the primary treat-
ment (within 36 months) might be due not only to per-
sistence of cancer cells after treatment, designated as
minimal residual disease, but also to the progressive devel-
opment of a new cancer from tumor-related precursor
lesions involving the field.1-4 Accordingly, the persistence
on surgical margins of genetic alterations clonally related
to the primary HNSCC is responsible for a higher risk of
true local recurrence.5-7 Subsequently, the concept of sec-
ond field tumor has been introduced for those cases show-
ing a minimal genetic discordance from the primary, such
recurrence being considered a new carcinoma clonally
related to the primary.8 Taken together, this hypothesis
has been postulated on the basis of genetic studies on bio-
logical samples obtained in surgical fields, where a mini-
mal residual disease or a genetically altered field with
progression potential may be left behind by the surgeon,
thus being responsible for local relapse.
Conversely, few data exist regarding the pathobiol-
ogy of the development of local recurrence after primary
RT that, at least in theory, might result from different
mechanisms from both biological and genetic points of
view. Several biological and local factors responsible for
radioresistance can create a situation comparable to the
persistence of a minimal residual disease in a surgical field.
Furthermore, analogously to surgery, irradiation might
have an impact only on malignant cells and may not affect
preneoplastic cells in the field, which undergo subsequent
malignant transformation, thus developing a second
primary malignancy genetically unrelated to the original
cancer. The transformational effect of irradiation on pre-
neoplastic cells in this latter process remains to be eluci-
dated. In any case, other mechanisms responsible for a
local recurrence after RT might exist. In fact, because of
heterogeneity in cancer cell subpopulations,9 different but
genetically related cells might show a different response to
irradiation; thus, it is likely that irradiation might exert a
selection pressure of more aggressive and radioresistant tu-
mor cells, which could be responsible for persistence/re-
currence of the tumor. This persistent/recurring cancer
caused by RT selection, therefore, might be genetically
related but different from the corresponding preirradiated
primary tumor, with potential therapeutic and prognostic
implications.
To test this hypothesis and to study the genetic alter-
ations involved in HNSCC post-RT recurrences, we ana-
lyzed both TP53 mutations and microsatellite patterns in
corresponding specimens of primary tumors and recur-
rences after RT in HNSCC patients who failed after pri-
mary RT. These patients were selected from a larger




From a historical series of 85 consecutive patients treated
by primary RT in whom TP53 gene analysis in the pri-
mary lesion revealed the presence of a mutation,10 we
selected a group of 16 patients in whom a recurrent
HNSCC appeared within 36 months and in a field within
2 cm from the index tumor. According to site, there were
12 squamous cell carcinomas (SCCs) of the larynx, 3 of
the oral cavity, and 1 of the oropharynx.
TP53 Gene Analysis
Formalin-fixed, paraffin-embedded tissue sections (7-8
lm) were used to microdissect tumor tissue from normal
tissue, which was then used for DNA extraction. Exons
5-8 of the TP53 gene were amplified using the primers
described by Gallo et al.10 Amplification consisting of 32
cycles was carried out in 25 lL of 1.5 mMMgCl2 Perkin
Elmer Cetus (Wellesley, Mass) buffer with 1 lM of exon-
flanking primer set, 50 lM each deoxynucleotide triphos-
phate, and 0.5 U Perkin Elmer Cetus AmpliTaq. Temper-
ature and time for the reaction cycles were 95C for 1
minute, 62C for 1 minute, and 72C for 30 seconds. Po-
lymerase chain reaction (PCR) products were heat dena-
tured and subjected to single-stranded conformational
polymorphism (SSCP) analysis using electrophoresis on
6% polyacrylamide gels with 5% to 10% glycerol. Elec-
trophoresis was performed at 45 W for 4 hours at 4C;
the gels were silver stained and dried on filter paper. All
samples were subjected to PCR and SSCP analysis at least
twice to confirm the results obtained. To exclude the
silent CGA/CGG dimorphism in codon 213, PCR prod-
ucts from samples showing SSCP abnormalities in exon 6
were subjected to restriction analysis with TaqI. Loss of
heterozygosity (LOH) was evaluated in those samples
missing mutation in relapsed tumors after RT. The poly-
morphism revealed by MspI digestion of a 107-bp frag-
ment obtained from amplification of p53 intron 6 was
used.11 Another intragenic short tandem repeat polymor-
phism (AAAAI)n was investigated.12
Nucleotide sequence was performed after elution
from acrylamide gels of abnormal bands detected by
SSCP analysis and amplification by PCR using the same
primers as used for SSCP analysis, with a modified 50 end
to contain the M13(-20) sequence. These PCR products
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were purified on 2% NuSieve gels, phenol extracted, and
subjected to automated sequencing with the Taq Dye
Primer Cycle Sequencing kit (Applied Biosystems, Foster
City, Calif). Both strands were sequenced for confirma-
tion of the mutations. TP53 wild-type samples were
directly sequenced from the original PCR products.
Microsatellite Analysis
Genomic DNA was extracted from peripheral blood and
surgical samples as previously described.7 Ten microsatel-
lite loci were amplified using published oligonucleotides.
Chromosomal location, type of polymorphism, sequen-
ces, annealing temperatures, and references are reported
in Table 1. To facilitate multiplexing, the primers were
designed to give rise to PCR products of a size difference
of at least 100 bp. The PCR reactions were carried out in
a volume of 30 lL and included 50 to 100 ng of genomic
DNA, 10mM Tris-HCl (pH 8), 50 mM KCl, 1.5 mM
MgCl2, 0.1% gelatin, 0.2% formamide, 2 to 8 pmol of
each oligonucleotide primer, 200 lmol of each deoxynu-
cleotide triphosphate, and 0.5 U of Taq polymerase. After
an initial denaturation at 94C, 40 cycles at 1 minute each
were performed at the annealing temperature (52-60C,
dependently by primers) and at 72C. A final extension
was done at 72C for 7 minutes.
Amplified PCR fragments were analyzed by 8% to
12% polyacrylamide gel electrophoresis and run at 20 W
for 3 to 4 hours. Bands were detected by silver staining as
already described.13 Microsatellite instability was scored
when the PCR products from the tumor shifted up or
down in respect to the band pattern of normal tissues, or
when there was evidence of LOH, defined as a>50% vis-
ual reduction in the signal intensity of 1 allele. In the case
of borderline allelic losses, the PCR reactions were
repeated and quantified by densitometric analysis (GS-
670 ImagingDensitometer, Bio-Rad Laboratories,Hercu-
les, Calif). In instances where the normal and tumor
DNAs did not amplify equally, the signals from the photo-
graphic bands from the allele retained by the tumor were
normalized to those of the corresponding bands of the con-
trol tissue either by repeat electrophoresis of adjusted vol-
umes of PCR products or by quantitative densitometry.
Statistical Analysis
Statistical analysis was performed using Stata software
(Stata Corporation, College Station, Tex). Comparison of
TP53 gene status and pattern of LOH/microsatellite
instability (MSI) between the index tumor and the recur-
rence where analyzed for their impact on disease-free
interval (DFI) between RT treatment and detection of the
recurrence and for actuarial survival after salvage surgery
Table 1. Characteristics of 10 Microsatellite Markers Used in This Study
Marker Chromosome
Localization
Gene Repeat Motif Primer Sequences (F/R)
D2S123 2p16 hMSH2 CA 50-GTGACTTGGATACCATCTATCTATC-30
50-CTGCCTTTAACAGTGCTATTT-30
D3S47 3q21-24 RPN1 CA 50-CGGGTACATTGGCCTGTAAG-30
50-GAGACTACGGCATTGCCA-30
BAT25 4q12 c-Kit A 50-TCGCCTCCAAGAATGTAAGT-30
50-TCTCATTTTAACTATGGCTC-30
IFN-a 9p21 p16INK CA 50-GTAAGGTGGAAACCCCCACT-30
50-TGCGCGTTAAGTTAATTGGTT-30
D9S156 9p21 p16INK CA 50-ATCACTTTTAACTGAGGAGG-30
50-AGATGGTGGTGAATAGAGGG-30
D9S171 9p21 p16INK CA 50-AGCTAAGTGAACCTCATCTCTGTCT-30
50-ACCCTAGCACTGATGGTATAGTCT-30
D16S260 16q22.1 E-cadherin CA 50-GGTTGAGATGCTGACATGC-30
50-CAGGGTGGCTGTTATAATG-30
TP53 17p12 p53 CA 50-ACTGCCACTCCTTGCCCCATTC-30
50-AGGGATACTATTCAGCCCGAGGTG-30
D17S261 17p12 p53 CA 50-CAGGTTCTGTCATAGGACTA-30
50-TTCTGGAAACCTACTCCTGA-30
D21S1245 21q21 AML-1 AAAG 50-GTCAGTATTACCCTGTTACCA-30
50-GTTGAGGATTTTTGCATCAGT-30
F indicates forward; R, reverse; IFN, interferon.
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using the Kaplan-Meier method and then using the log-
rank test for comparison between 2 groups.
RESULTS
Comparison of TP53 Gene Status in
Pre- and Postirradiation Tumor Samples
According to the site of mutation, we observed a TP53
point mutation in 4 cases in exon 5 (all were laryngeal
SCCs), 1 case in exon 6 (a laryngeal SCC), 5 cases in exon
7 (3 were laryngeal SCCs), and finally 5 cases in exon 8 (3
were laryngeal SCCs). Moreover 1 laryngeal carcinoma
showed a band shift in both exon 5 and exon 8.
An identical TP53 gene mutation was detected in
both pre- and postirradiated failed tumors in 11 of 16
(68.75%) cases analyzed. Exon 5 and 8 were prevalently
affected in this group.
Conversely, 5 tumors showed a different TP53 gene
status in comparison with the original preirradiated pri-
mary tumors. In detail, all 5 (31.25%) cases lost their orig-
inal TP53 mutations in the postirradiated biopsy
specimens; the missed mutations clustered in exon 5 in 4
cases, whereas 1 case involved exon 8.
To assess the nature of the lack of TP53 mutations
in the samples from relapsed tumors that were originally
mutated, preirradiated tumor samples were typed at 2
intragenic p53 polymorphisms.10,11 All 5 cases were in-
formative for at least 1 system and were assayed for LOH
in the postirradiated samples; no allelic losses were found.
Comparison of LOH/MSI Patterns in
Pre- and Postirradiation Tumor Samples
Microsatellite analysis was performed in pre-RT and post-
RT tumor biopsies from the 16 TP53 mutated informa-
tive cases. In 8 of 16 patients, different LOH/MSI pat-
terns were documented in pre-RT and post-RT recurring
SCC. In total, 7 discordant allelic losses and 8 discordant
microsatellite alterations were found in the LOH/MSI
genetic assessment (Fig. 1). In 2 cases, Patients 2 and 11,
2 discordant losses and 1 microsatellite alteration were
documented comparing LOH/MSI pattern from pre-RT
and post-RT samples. In 3 cases (Patients 4, 12, and 16),
1 discordant allelic loss and 1 microsatellite alteration
were noted between pre- and post-RT biopsies. Finally,
Patients 1, 8 and 10 showed a single genetic discordance
as a microsatellite alteration between pre- and post-RT
tumors.
Considering the comparison between pre- and post-
RT SCC, we documented the appearance of new genetic
alterations in post-RT tumor biopsies from all 3 cases
with complete discordance of both TP53 and LOH/MSI
status, whereas in the 3 cases with TP53 concordance and
LOH/MSI discordance, the postirradiated sample showed
lack of genetic alteration at microsatellite loci.
Cumulative Comparison of TP53 Gene Status
and Pattern of LOH/MSI
Overall, the comparison of genetic assessment including
TP53 gene and microsatellite analyses showed that in 8
cases (Patients 3, 5, 6, 7, 9, 13, 14, and 15) a complete
genetic concordance was documented, whereas in the
remaining 8 cases there was discordance (Fig. 2). In detail,
in 3 cases (Patients 2, 4, and 12) both TP53 gene status
and LOH/MSI pattern were discordant; in another 3 cases
(Patients 1, 8, and 16) despite a TP53 concordance
between pre- and postirradiation tumor samples, a differ-
ent LOH/MSI pattern was documented, and finally in the
remaining 2 cases (Patients 10 and 11) a genetic concord-
ance was documented only in the LOH/MSI pattern,
whereas the post-RT samples lost the TP53 gene mutation
documented in the corresponding preirradiation tumor
biopsy.
Clinical Outcome According to
Genetic Analysis
Follow-up data were available on all informative patients
and revealed differences in both disease-free and overall
survival. We found that those patients without changes in
TP53 gene status and LOH/MSI pattern between pre-
and post-RT had a longer DFI before relapse and better
survival when compared with those showing a discordant
genetic pattern (log-rank test, P ¼ .0045) (Fig. 3). The
shortest DFI was documented in those HNSCCs with dis-
cordance at 1 genetic test between pre- and postirradiation
biopsies (TP53 concordance and LOH/MSI discordance
in 3 cases; TP53 discordance and LOH/MSI concordance
in 2 cases), and the comparison among the group was still
significant (log-rank test, P¼ .0012).
A surgical salvage after RT failure was attempted for
all relapsed cases; however, in 5 patients this was unsuc-
cessful, and patients died from disease. According to
genetic assessment, 2 of these (Patients 3 and 15) showed
an identical TP53 and LOH/MSI pattern among pre- and
postirradiation samples (suggestive for a true recurrence
after RT failure), whereas the remaining deaths were
documented among 1 patient (Patient 2) with complete
discordant genetic pattern (suggestive for a second pri-
mary malignancy) and the only 2 patients (Patients 10
and 11) who lost TP53 mutation in recurring lesions
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Figure 1. Microsatellite and p53 analysis before (pre) and after (post) radiotherapy (RT) is shown.
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without any discordance in LOH/MSI pattern analyzed.
According to Kaplan-Meier survival analysis, differences
among groups were statistically significant (log-rank test,
P¼ .0002).
DISCUSSION
In this study, we attempted to define the pathobiology of
locally recurring HNSCC after curative RT. In this light,
we selected patients who had relapse within a period of 36
months after the end of radiation treatment and at a dis-
tance <2 cm from the first carcinoma, and we compared
TP53 gene status and microsatellite analyses in samples of
pre- and post-RT recurring lesions. Here, we first postu-
late that a local recurrence after primary radiation therapy
might have similar aspects but also a different pathobiol-
ogy from a recurrence after surgery.
In our limited series, we found 8 cases with complete
concordance of the genetic tests that could be interpreted
as true RT-failed recurrences of the original HNSCC.
Furthermore, we detected a complete discordance
between pre- and post-RT biopsies in 3 cases, indicating
the appearance of a new carcinoma genetically unrelated
to the primary tumor and, thus, definable as a second
primary.
Interestingly, in the remaining 5 cases, genetic anal-
yses of both TP53 and LOH/MSI status showed pre- and
post-RT concordance in only 1 test.
In this series, we observed a better disease-free sur-
vival in patients with discordance of both TP53 gene
and LOH/MSI status (second primary) in comparison
with the cases showing genetic discordance at 1 test,
and among them we documented a shorter DFI and
overall survival in the 2 cases with lack of TP53 muta-
tion in the postirradiation sample. The absence of new
additional genetic alterations with the exception of the
lack of TP53 mutation in these 2 cases, together with
their worse prognosis, could suggest that these relapses
reflect a RT-induced selection of more aggressive, less
RT-sensitive clones within the tumor mass. In other
words, these 2 cases might represent genetically selected
true recurrences. In fact, the particularly short DFI
between RT and recurrence (<3 months) clinically clas-
sifies them as persistence that should be expected to be
totally genetically concordant with the original cancer;
the evidence of a genetic discordance might be related
to the selection impact of RT confirmed by the worse
prognostic impact.
The remaining 3 discordant cases with more
favorable prognosis, in which the discordance was lim-
ited to LOH/MSI pattern, might represent a new ge-
netically related carcinoma from a common field,
second field tumor, in which the role of irradiation in
determining its development is not yet defined, but
possibly preneoplastic clones genetically related to the
primary tumor that are not killed by RT because they
are not yet neoplastic subsequently undergo neoplastic
transformation.
The possibility of defining the pathobiology of post-
RT recurring cancers in HNSCC patients also by genetic
assessment of tumor DNA represents a challenge for
researchers. However, except in the case of detection of
solid tumors with a specific histology (ie, sarcoma) or car-
cinomas with specific RT-induced DNA aberrations sug-
gestive of RT-induced second primary HNSCC,14,15 the
time interval between the development of the primary and
of the recurrent cancer might help in most cases. It is likely
that a few cancer cells surviving irradiation take less time
Figure 3. Kaplan-Meyer disease-free interval (radiotherapy re-
currence) is shown between patients with concordance and
those with discordance of TP53 and loss of heterozygosity/
microsatellite instability mutations.
Figure 2. Comparison of genetic assessment is shown. RT
indicates radiotherapy; LOH, loss of heterozygosity; MSI,
microsatellite instability.
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to grow into a clinically detectable tumor (presumably
also because of their increased aggressiveness) than a field
of preneoplastic cells needs for malignant progression to
invasive carcinoma.
In conclusion, we have found that even if the reap-
pearance of a new carcinoma does meet clinical criteria to
be considered a recurrence, from the genetic point of view
things are more heterogeneous. Whereas a true recurrence
or a true second primary HNSCC seem to be clearly de-
finable, less is known about the pathobiology of those car-
cinomas showing genetic discordance among pre- and
post-RT sample biopsies.
Hopefully our results will be more consistently clari-
fied with larger numbers and longer follow-up than in this
limited series. If our data are confirmed by further studies,
then the genetic characterization of the recurrence, espe-
cially in those cases with a particularly short DFI, might
acquire a useful clinical relevance, while planning salvage
therapeutic strategy.
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